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I. Meta-Analysis: Racial Disparities in Prostate Cancer Survival 
Prostate cancer is the second leading cause of cancer-related mortality in men. Previous 
studies have drawn inconsistent conclusions on racial differences in prostate cancer 
survival. This meta-analysis was conducted to investigate the relationship between race 
and survival from prostate cancer. A systematic review of published articles from 1968 to 
2007 assessing survival from prostate cancer among African American and White men was 
conducted. The search yielded 20 eligible published manuscripts. Analysis of unadjusted 
studies showed African American men have an increased risk of all-cause mortality 
(Hazard ratio (HR) = 1.47, 95% confidence interval (CI): 1.31, 1.65, P < 0.001). However, 
examination of adjusted studies showed no difference (HR = 1.07, 95% CI: 0.94, 1.22, P = 
0.308). No statistically significant difference was observed in prostate cancer-specific 
survival in both analyses using unadjusted (HR = 1.11, 95% CI: 0.94, 1.31, P = 0.209) and 
adjusted studies (HR = 1.15, 95% CI: 0.95, 1.41, P = 0.157). There was evidence of 
heterogeneity that was unexplained by factors analyzed in overall survival but explained by 
stage in prostate cancer-specific survival. This meta-analysis concludes that there are no 
racial differences in the overall and prostate cancer-specific survival between African 
American and White men. 
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II. Case-Control study: Association between Family History of Cancers and Prostate 
Cancer 
Family history of prostate cancer is an established risk factor for prostate cancer. However, 
the relationship between family history of cancers other than prostate cancer and prostate 
cancer risk is inconclusive. This study sought to examine the association between family 
history of cancers and prostate cancer. A case-control study was conducted in which cases 
and controls were randomly selected from a large urology clinic in Central Virginia. Cases 
were 600 histologically confirmed prostate cancer patients who were diagnosed between 
January 2000 and December 2005, and controls were 686 patients who visited the clinic 
during the same period and diagnosed with urological illnesses other than cancers and 
prostate-related problems. Data on family history of cancers, lifestyle and demographic 
factors were collected. Unconditional logistic regression analysis was used to estimate the 
odds ratios and the corresponding 95% confidence intervals after adjustment for potential 
confounding factors. Multiple comparisons adjustments were made using Bonferroni 
adjustment. Men with family history of any cancer in first-degree relatives including 
parents (OR=2.42, 95% CI: 1.53, 3.84) and parents only (OR=1.90, 95% CI: 1.23, 2.94) 
were at increased risk of developing prostate cancer compared to men with no such family 
history of cancer. Significant increased risk was also observed with family history of 
prostate cancer in first-degree relatives (OR=2.68, 95% CI: 1.53, 4.69) and parents only 
(OR=3.26, 95% CI: 1.71, 6.24) compared to men with no family history of prostate cancer. 
Even after adjustments for multiple comparisons, the significance persisted both in first-
degree relatives (OR=2.68, 95% CI: 1.16, 6.21) and parents alone (OR=3.26, 95% CI: 
   
 x
1.24, 8.63). No association was found with family history of other cancers including 
breast, colon, lung, skin, digestive tract, stomach, liver, pancreas, female cancers, 
urogenital, urinary bladder, brain, blood and lymph node and other cancers and risk of 
prostate cancer. This study demonstrated an increased prostate cancer risk for men with a 
family history of any cancer or prostate cancer in first-degree relatives including parents 
and parents alone. Health care providers need to be aware of the potential risk of family 
history of cancers on prostate cancer. 
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III. Case-Control study: Association between Obesity and Prostate Cancer 
Obesity is a major public health problem in the United States. Several studies have 
investigated the association between obesity and prostate cancer risk. However the impact 
of early-adult obesity on prostate cancer is not well studied. This study proposes to 
investigate the relationship between prostate cancer and early-onset obesity and current 
obesity. A case-control study was conducted to investigate the relationship between 
obesity and prostate cancer in a large urology clinic population in Central Virginia. Cases 
included histologically confirmed prostate cancer patients of all stages and grades 
diagnosed from January 2000 to December 2005. Controls were patients who were 
diagnosed with urological illness other than cancers and prostate-related problems. Self-
reported data was collected on anthropometric, lifestyle and demographic factors through a 
mail survey. Unconditional logistic regression analysis was conducted to investigate the 
association between prostate cancer and early-onset obesity (BMI at age 18) and current 
obesity. Odds ratios and corresponding 95% confidence intervals were calculated after 
accounting for significant interaction terms and adjusting for potential confounding 
variables. This study showed statistically significant association between BMI at age 18 
and prostate cancer risk in the multivariate analysis when BMI was evaluated as a 
continuous variable. There was a 7% decrease in the odds of prostate cancer risk for every 
1 kg/m2 increment in BMI at age 18 (OR=0.93, 95% CI: 0.87, 0.98). Analysis of BMI at 
age 18 as a categorical variable also showed reduced risk though statistically non-
significant. Obese men (OR=0.62, 95% CI: 0.12, 3.08) and overweight men (OR=0.60, 
95% CI: 0.35, 1.05) had a non-significant decreased risk of developing prostate cancer 
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compared to normal weight men at age 18. Examination of current BMI showed a non-
statistically significant decreased risk of prostate cancer when examined as a continuous 
variable. However, there was significant interaction between current BMI treated 
categorically and age. This study concludes that there is decreased prostate cancer risk 
associated with increasing BMI at age 18. Future large prospective studies are needed to 
better understand the association between early-onset obesity and risk of prostate cancer 
and explore the biological factors associated especially in the early ages. This document 
was created in Microsoft Word 2003.  
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META-ANALYSIS: RACIAL DISPARITIES IN PROSTATE 
CANCER SURVIVAL 
 
 
INTRODUCTION 
 Prostate cancer is the most common cancer in men excluding basal and squamous 
cell skin cancer. In 2008, approximately 186,320 new cases are estimated to be diagnosed 
with prostate cancer in the United States.1  This estimate accounts for 25% of all the 
cancers diagnosed in men.1 African American men have the highest incidence rates of 
prostate cancer. The risk of prostate cancer in African Americans is 60% higher than 
White men.2 Prostate cancer is the second leading cause of cancer-related mortality in 
men. In the United States, approximately 28,660 men will die from prostate cancer in 
2008 alone; accounting for approximately 10% of all the cancers deaths in men.1 The 
mortality rate from prostate cancer is 2.4 times higher in African Americans compared to 
White men.3   
            More than 90% of prostate cancers are diagnosed in the local and regional stages 
and the 5-year relative survival for these cancers is 100%.1 However, the 5-year relative 
survival for distant prostate cancer is significantly lower (31.9%).1 Although overall 
survival rates are high, rates differ by race; the 5-year survival rates are approximately 
7% higher for Whites than African Americans at all stages. The 5-year survival rate for 
localized cancer is approximately 93% for Whites and 86% for African Americans.4  
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Disparity in survival rate is also documented for regional (83% vs. 68%) and metastatic 
cancers (29% vs. 22%).4    
 Although descriptive studies show that African Americans are disproportionately 
affected by this disease compared to Whites, it is not clear if the increased mortality is 
due to race or factors affecting this population such as access to care, quality of care, 
socio-economic status, stage and grade of tumor, treatment and comorbidity. Several 
researchers have attempted to clarify this disparity by controlling for some of the above 
mentioned confounding factors; however, these studies have produced inconsistent 
findings.4-19  Several studies have shown that there is an association between race and 
survival from prostate cancer4, 15-19  whereas other studies have not found such an 
association.5-14    
 Although several observational studies have had conflicting findings, to our 
knowledge there are only two meta-analyses conducted examining the impact of race on 
survival from prostate cancer. Overall survival is defined as death due to any cause and 
prostate cancer-specific survival is death from prostate cancer as the underlying cause. 
The first meta-analysis, by Bach et al. in 2002, included 17 studies that examined racial 
differences in prostate cancer survival between Whites and African Americans who 
received the same treatment for similar stages of cancer.20 The study showed that African 
Americans had a statistically significant increased risk of mortality due to all causes. But 
this statistical significance disappeared after adjusting for other causes of death derived 
indirectly from population mortality rates from the National Center for Health Statistics 
1997 decennial life tables to account only for cancer-specific mortality. This manuscript 
examined similar cohorts of men receiving same treatment and similar stages of disease 
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and also used indirect adjustment for other causes of death to account for prostate cancer-
specific mortality. These results are not generalizable to men with all stages of the 
disease who are receiving different treatments and this problem was addressed in the 
recent meta-analysis by Evans et al.21  They derived the estimates for prostate cancer-
specific mortality directly instead of applying indirect population adjustments.   
 Evans et al. evaluated 28 studies exploring all-cause and prostate cancer-specific 
mortality as potential outcomes.21  The study showed increased statistically significant 
risk for overall survival (Hazard ratio (HR) = 1.35, 95% confidence interval (CI): 1.23, 
1.48, P < 0.001) and prostate cancer-specific survival (HR = 1.29, 95% CI: 1.13, 1.47, P 
< 0.001) among African Americans compared to Whites when using the studies that did 
not adjust for any confounders or adjusted only for age. When studies that adjusted for 
age, clinical and other socioeconomic factors were used this statistical significance 
disappeared for the overall survival (HR = 1.01, 95% CI: 0.88, 1.16, P = 0.93); however, 
prostate cancer-specific survival still showed a marginal increased risk of mortality for 
African Americans compared to Whites (HR = 1.13, 95% CI: 1.00, 1.27, P = 0.052). 
 Although this meta-analysis included all the key articles, there was a major 
methodological drawback. The authors have included more than one article from the 
same SEER cancer registry data, which represented overlapping time periods and 
included the same SEER location (San Francisco Bay region) for prostate cancer-specific 
mortality.10, 11, 16, 22 When the meta-analysis was repeated after removing the two SEER 
articles namely Du et al10 and Polednak et al,11 the increased risk was not statistically 
significant (HR = 1.14, 95% CI: 0.95, 1.36, P = 0.15) (confidence interval and P value 
obtained through communication with the author). However the article did not discuss 
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this crucial information and reported increased risk among African American men for 
prostate cancer-specific mortality.           
 We conducted a meta-analysis of studies that exclusively address the impact of 
race, not just as a primary exposure variable, but also as one of the potential independent 
variables, on survival in men for localized and advanced prostate cancer. This meta-
analysis mitigates the limitations in the previous meta-analyses.20, 21 Recognizing the 
varied nature of the studies in terms of standard errors, sample sizes and adjustments for 
potential confounding variables, this study utilized two distinct methodologies to 
examine the association. 
MATERIALS AND METHODS 
Study selection 
 
 A Medline/PubMed search of published articles in English from 1968 to 2007 was 
performed. We used keywords and MESH terms including terms as “prostate cancer”, 
“survival”, “mortality” and “race”. We used three levels of screening to select relevant 
publications for this analysis. First, two independent reviewers examined all the 
identified abstracts to find relevant publications using the criteria that included race as the 
primary exposure variable, or at least one of the covariates, and survival either overall or 
prostate cancer-specific survival as the outcome. Second, each relevant publication was 
examined thoroughly to determine that the inclusion criteria were fulfilled. Additionally, 
the reference section of the selected relevant publications was examined for additional 
publications that were missed in the initial search. Third, the selected publications were 
reviewed and abstracted. At this stage, publications from the same data sources, place and 
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overlapping time periods were identified and made sure that only one publication was 
selected.  
Inclusion and exclusion criteria 
 The inclusion criteria for this meta-analysis included original research 
manuscripts that: a) were published between 1968 and 2007, b) had race, specifically 
Whites and African Americans, as the main exposure variable or covariate, c) had overall 
survival or prostate cancer-specific survival as one of the outcome variables, d) provided 
estimates from which log hazard ratios and standard errors can be calculated directly or 
indirectly. We included articles published in English. Review articles or letters were not 
included in this analysis. Manuscripts that either compared blacks to non-blacks or non-
whites to whites were also excluded from the analysis. 
When there were several publications from the same data source, such as the 
SEER cancer registry data, with overlapping time frames and locations, only one 
publication was selected to be included in the analysis. Factors such as the most recent 
year of publication, larger sample size, number and types of confounders examined, 
longer follow-up period, and inclusion of relevant effect sizes were considered to select 
publications. Although the initial search yielded 505 publications, only 20 articles met the 
inclusion criteria for this analysis (Figure 1). Detailed descriptions of the selected studies 
are available in supplementary data. 
Out of the 20 publications, 17 studies provided estimates for overall survival.5-10, 
23- 33 Thirteen manuscripts had estimates available to calculate the crude overall survival 
hazard ratios and 95% confidence intervals directly (2 studies)23, 24  or indirectly from 
Kaplan-Meier survival curves (11 studies).5-7, 8, 10, 28-33  Eight manuscripts had estimates 
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available to calculate the adjusted overall survival hazard ratios and 95% confidence 
intervals directly.7, 9, 10, 23- 27  Prostate cancer-specific survival was reported in nine 
manuscripts.10, 12, 23, 25-27, 31, 34, 35  Six manuscripts had estimates available to calculate the 
crude hazard ratios and 95% confidence intervals for prostate cancer-specific survival 
directly (2 studies)23, 34  or indirectly from Kaplan-Meier survival curves (4 studies).10, 12, 
31, 35  Seven manuscripts had estimates available to calculate the adjusted hazard ratios 
and 95% confidence intervals for prostate cancer-specific survival directly.10, 12, 23, 25- 27, 34  
Some studies provided both unadjusted and adjusted estimates, while others reported only 
the unadjusted or adjusted effect sizes. 
Data abstraction 
 Data abstraction form was developed and two independent reviewers abstracted 
relevant information from the selected publications. Information including bibliographic 
information (authors, title, journal of publication and date, whether peer reviewed or not), 
study setting (study location, type, name and data source), study population 
characteristics (age, race, stage and grade of cancer), study design details (sample size, 
year of prostate cancer diagnosis, length of follow-up), model characteristics (exposure 
variable, outcome variable, other covariates assessed and controlled for confounders) and 
study results (hazard ratios and 95% confidence intervals or p values from Cox 
proportional hazard regression, Kaplan-Meier survival curves) were abstracted. 
Statistical analysis 
 The selected publications reported different estimates for the association between 
race and survival, including hazard ratios and 95% confidence intervals or P values from 
Cox proportional hazard regression or Kaplan-Meier survival curves. We used log hazard 
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ratios and standard errors to determine the summary hazard ratios and 95% confidence 
intervals. The method described by Parmar et al was used to derive the log hazard ratios 
and standard errors directly for the manuscripts providing hazard ratios and 95% 
confidence intervals or P values.36 The log hazard ratios and standard errors were 
determined indirectly for the crude analysis using Parmar et al.36 and Microsoft Excel 
spreadsheets provided by Tierney et al.37 from Kaplan-Meier survival curves.
 Depending on the results of the tests for heterogeneity including Q statistic and I2 
statistic a decision was made whether to use fixed effects or Dersimonian-Laird random 
effects model. As the tests for heterogeneity was significant in all the analysis, random 
effects model results are reported.  
 To account for the differences among the studies in terms of standard errors, 
sample size and adjustment for confounders, weighted analysis was considered. 
Weighting the studies with respect to standard errors is straight forward. In addition to 
this, weighting the studies according to their other characteristics that are considered 
important in public health studies was also considered. We believe studies that adjust for 
these variables provide valid information about the racial differences than those that do 
not and therefore, the studies with adjusted analysis received a higher weight. For this 
purpose an objective quality scoring method was utilized to assign scores to each study.  
 Previous publications have provided mixed opinions on whether quality scoring 
should be used as a weighting variable. Some manuscripts comment that quality scoring 
adds subjective bias, may lack validity and results may not represent quality. 38-41 Other 
studies claim that quality scoring can be done, but recommend not using the scores as 
weights but rather use the summary score as a covariate to conduct subgroup and 
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sensitivity analysis. 40, 42, 43  As suggested in the literature, this study utilized standard 
error as weighting variable and investigated if the analysis using summary score as 
weighting variable also holds true with this analysis. These two distinct methods were 
considered to maximize the validity of this meta-analysis. 
In order to preserve objectivity of the scoring, only the factors that are important 
predictors of prostate cancer and those that do not pose any scoring ambiguity, such as 
age of the patient, stage of the disease, grade of the tumor, treatment, comorbidity, 
socioeconomic status, pre biopsy PSA levels and sample size of the study were 
considered. Moreover, two independent researchers scored these studies so that reliability 
could be established. Based on the quality scores, weights proportional to the scores were 
calculated. That is, a study with higher score received a higher weight. Then the analysis 
was performed in two ways: first, with weights obtained from standard errors alone, then 
by using summary weights that are averages of the weights based on the standard errors 
and the weights based on the quality scores.  
Funnel plots were used to examine publication bias. Sensitivity analysis was 
performed to determine robustness of the meta-analysis. To examine the effects of small 
and outlier studies we removed one study at a time and repeated the analysis with the 
remaining studies. Further subgroup and meta-regression analysis were done on selected 
covariates to identify potential explanations for heterogeneity among studies. All analysis 
was done using STATA Statistical software version 10.1 (StataCorp, College Station, 
TX). All p-values were two-sided and values less than 0.05 were considered significant. 
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RESULTS 
(A) Overall survival 
Unadjusted and adjusted summary estimates using standard error as weights. 
Pooled estimate from the 13 studies with unadjusted estimates showed a statistically 
significant increased risk of mortality among African American men compared to White 
men (HR = 1.47, 95% CI: 1.31, 1.65, P < 0.001). However, no statistically significant 
difference was observed in the analysis using the adjusted hazard ratios from the eight 
studies that adjusted for age, clinical and other demographic variables (HR = 1.07, 95% 
CI: 0.94, 1.22, P = 0.308). Figure 2 shows that there was evidence of heterogeneity 
among the studies in the adjusted analysis (Q = 36.45, df 7, P < 0.001). 
Adjusted summary estimates using summary score as weights. Utilizing summary 
score as weights evenly distributed the weights among the studies compared to using 
standard error as weights. Conversely, the summary estimates from the eight adjusted 
studies remained the same (HR = 1.06, 95% CI: 0.90, 1.25, P = 0.463) compared to the 
pooled estimates obtained using standard error as weights.              
Table 1 compares the summary estimates derived from the standard error and 
summary score methods for the unadjusted, adjusted and overall analysis. The findings 
from the two methods were fairly similar and comparable. 
Publication bias. Figure 3 shows equal dispersion of studies. Both the unadjusted 
and adjusted models showed no evidence of publication bias in the funnel plots. 
Sensitivity analysis. Small studies and potential outliers were identified using 
standard errors and funnel plots. These studies were removed one at a time and the 
summary estimates were evaluated each time. In the unadjusted analysis, removal of the 
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following small studies and outliers provided the following estimates: Zagars et al (HR = 
1.44, 95% CI: 1.29, 1.61, P < 0.001)29, Powell et al (HR = 1.52, 95% CI: 1.35, 1.71, P < 
0.001)6 , and Hussain et al (HR = 1.38, 95% CI: 1.27, 1.49, P < 0.001).33 Eliminating all 
three manuscripts at the same time yielded similar results as the overall unadjusted 
analysis (HR = 1.35, 95% CI: 1.29, 1.41, P < 0.001). 
 In the adjusted analysis, removing the following studies resulted in the following 
estimates: Halabi et al (HR = 1.12, 95% CI: 0.99, 1.28, P = 0.069)25 , Freeman et al (HR 
= 1.02, 95% CI: 0.91, 1.14, P = 0.745)27 , and Optenberg et al (HR = 1.10, 95% CI: 0.97, 
1.25, P = 0.155).7 Excluding all the three manuscripts at the same time produced similar 
results as the overall adjusted analysis (HR = 1.08, 95% CI: 1.00, 1.17, P = 0.065). 
Subgroup and Meta-regression analysis. Subgroup and meta-regression analysis 
were conducted across several covariates to explain the heterogeneity among the studies 
(Table 2 and 3). The analysis showed that the heterogeneity observed among the studies 
examining overall survival cannot be explained by any of the covariates including stage, 
recruitment year or study type.  
(B) Prostate cancer-specific survival 
Unadjusted and adjusted summary estimates using standard error as weights. 
Evaluation of the six studies with unadjusted estimates showed no statistically significant 
excess risk of prostate cancer-specific mortality among African American men compared 
to White men (HR = 1.11, 95% CI: 0.94, 1.31, P = 0.209). Similarly, analysis of the 
seven studies with the adjusted estimates also showed no increased risk among African 
American men compared to White men (HR = 1.15, 95% CI: 0.95, 1.41, P = 0.157). 
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Further examination of these studies showed evidence of heterogeneity among the studies 
in the adjusted analysis (Q = 22.46, df 6, P = 0.001) (Figure 4). 
Adjusted summary estimates using calculated summary score as weights. A 
modest difference in weights occurred when quality scores were added to the weights 
obtained from standard errors, compared to the weights from standard error alone. The 
pooled estimates from the seven adjusted studies did not change (HR = 1.17, 95% CI: 
0.96, 1.43, P = 0.113) compared to the estimates obtained using standard error as 
weights. Summary estimates derived from the standard error and summary score methods 
yielded consistent findings for the unadjusted, adjusted and overall analysis (Table 4). 
Publication bias. Funnel plots showed equal dispersion of studies and no evidence 
of publication bias in both unadjusted and adjusted models (Figure 5). 
Sensitivity analysis. Exclusion of Fowler et al (HR = 1.17, 95% CI: 1.02, 1.33, P 
= 0.022)12 , Kim et al (HR = 1.05, 95% CI: 0.90, 1.23, P = 0.520)31 , Roach et al (HR = 
1.07, 95% CI: 0.91, 1.26, P = 0.435)23  and all manuscripts at the same time (HR = 1.05, 
95% CI: 0.97, 1.15, P = 0.229) yielded similar findings as the overall unadjusted 
analysis. 
 In the adjusted analysis, removing studies including Halabi et al (HR = 1.22, 95% 
CI: 1.09, 1.35, P < 0.001)25, Freeman et al (HR = 1.08, 95% CI: 0.90, 1.31, P = 0.395)27 , 
and both manuscripts at the same time (HR = 1.18, 95% CI: 1.06, 1.32, P = 0.003) 
resulted in statistically significant estimates compared to the summary estimates obtained 
in the pooled adjusted analysis. 
Subgroup and Meta-regression analysis. The heterogeneity among the studies 
examining the association between race and prostate cancer-specific survival can be 
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explained by stage of the disease including local/regional (HR = 1.17, 95% CI: 1.04, 
1.32, P = 0.009), metastatic (HR = 0.76, 95% CI: 0.63, 0.92, p=0.005), recruitment 
period in 1987 or earlier (HR = 1.19, 95% CI: 1.02, 1.38, P = 0.026) and retrospective 
cohort study types (HR = 1.22, 95% CI: 1.07, 1.39, P = 0.004) in the subgroup analysis 
and by metastatic stage in the meta-regression analysis (Table 5 and 6). 
DISCUSSION 
 This study found no statistically significant increased risk of mortality due to all 
causes and prostate cancer-specific causes in African American men compared to White 
men. These results were consistent with the observations made by Bach et al who showed 
no increased risk in African Americans compared to Whites for prostate cancer-specific 
survival.20 While the overall survival results of this study was consistent to the findings 
observed by Evans et al., inconsistency between the two studies was observed in the 
prostate cancer-specific mortality.21 Evans et al. showed increased risk in prostate cancer-
specific survival whereas this study observed no increased risk.21 
 The major reason for this discrepancy in the prostate cancer-specific survival 
analysis between these studies may be due to the differences in manuscript selection. This 
meta-analysis only included one manuscript from the SEER cohort that spanned across all 
11 SEER sites, that is most recent, had a large sample size and was comprehensive.10 
However, Evans et al21 utilized four studies from the SEER cohorts that not only had 
overlapping time periods but also included the San Francisco Bay region (Table 7).10, 11, 
16, 22 When Evans et al. conducted sensitivity analysis and excluded Du et al10 and 
Polednak et al11 from the prostate cancer-specific survival analysis, they also observed no 
increased risk (HR = 1.14, 95% CI: 0.95, 1.36, P = 0.15) consistent with our analysis.  
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 This manuscript excluded some studies due to the inclusion/exclusion criteria for 
reasons including estimates not available.44-46 Additionally, this study included only one 
publication from University of Texas MD Anderson Cancer Center47 and SEER 
cohorts.11, 16, 18, 22  
Unlike other studies, this meta-analysis has several strengths. It addresses and 
accounts for serious methodological flaws observed in other studies. The study excluded 
more than one manuscript from the SEER registry data with overlapping time periods and 
only included one publication from the SEER registry data. Additionally, this study 
evaluated all published manuscripts from 1968 to 2007 and excluded manuscripts not 
meeting the inclusion criteria compared to the earlier meta-analyses.  
 The limitations of this study include that it only includes published manuscripts 
from 1968 to 2007. This excludes unpublished studies and usually unpublished studies 
are more likely to show negative results. Therefore this study may be overestimating the 
summary hazard ratios due to exclusion of those manuscripts. However, the tests showed 
no evidence of publication bias. In the adjusted analysis there was evidence for 
heterogeneity that was accounted for by performing random effects modeling, subgroup 
analysis and meta-regression analysis. However, the potential still exists for a lack of 
homogeneity among all the studies used to produce the summary hazard ratios. 
In conclusion, there are no differences between African American and Whites in 
survival from prostate cancer. Future studies are needed to study the racial disparity in 
prostate cancer survival. 
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Table 1. Summary Estimates Comparing Standard Error and Summary Score Methods for 
Overall Survival 
 
 Standard error  Summary score 
Unadjusted 1.47 (1.31, 1.65), P <0.001 1.52 (1.31, 1.78), P <0.001 
Adjusted 1.07 (0.94, 1.22), P = 0.308 1.06 (0.90, 1.25), P = 0.463 
Overall 1.29 (1.13, 1.47), P <0.001 1.30 (1.12, 1.52), P = 0.001 
*All P values are two-sided 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Subgroup Analysis for Overall Survival 
 
Subgroups  Summary 
hazard ratios 
95% confidence 
intervals 
P value No. of 
studies 
Stage      
 Local/regional 1.02 0.98, 1.06 0.424 3 
 Metastatic 0.88 0.60, 1.30 0.511 3 
 All stages  1.39 0.90, 2.13 0.135 2 
Recruitment 
period in PSA 
era or earlier 
     
 Yes 1.06 0.91, 1.22 0.470 4 
 No 1.11 0.88, 1.40 0.370 4 
Study type      
 Randomized 
control trial 
1.03 0.77, 1.40 0.830 3 
 Retrospective 
cohort study 
1.09 0.93, 1.29 0.285 5 
*All P values are two-sided 
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Table 3. Meta-regression Analysis for Overall Survival 
Subgroups  Summary 
hazard ratios 
95% confidence 
intervals 
P value 
Stage     
 Local/regional 1.00 - - 
 Metastatic 0.69 0.43, 1.12 0.131 
 All stages  1.37 0.87, 2.16 0.172 
Recruitment 
period in PSA 
era or earlier 
    
 Yes 0.83 0.57, 1.20 0.317 
 No 1.00 - - 
Study type     
 Randomized 
control trial 
1.27 0.81, 1.98 0.305 
 Retrospective 
cohort study 
1.00 - - 
*All P values are two-sided 
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Table 4. Summary Estimates Comparing Standard Error and Summary Score Methods for 
Prostate Cancer-Specific Survival 
 
 Standard error  Summary score 
Unadjusted 1.11 (0.94, 1.31), P = 0.209 1.14 (0.91, 1.44), P = 0.262 
Adjusted 1.15 (0.95, 1.41), P = 0.157 1.17 (0.96, 1.43), P = 0.113 
Overall 1.12 (0.97, 1.30), P = 0.128 1.16 (0.98, 1.38), P = 0.092 
*All P values are two-sided 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5. Subgroup Analysis for Prostate Cancer-Specific Survival 
Subgroups  Summary 
hazard ratios 
95% confidence 
intervals 
P value No. of 
studies 
Stage      
 Local/regional 1.17 1.04, 1.32 0.009 4 
 Metastatic 0.76 0.63, 0.92 0.005 1 
 All stages  1.47 0.99, 2.17 0.055 2 
Recruitment 
period in PSA 
era or earlier 
     
 Yes 1.19 1.02, 1.38 0.026 4 
 No 1.14 0.75, 1.72 0.540 3 
Study type      
 Randomized 
control trial 
0.97 0.59, 1.59 0.899 2 
 Retrospective 
cohort study 
1.22 1.07, 1.39 0.004 5 
*All P values are two-sided 
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Table 6. Meta-regression Analysis for Prostate Cancer-Specific Survival 
Subgroups  Summary 
hazard ratios 
95% confidence 
intervals 
P value 
Stage     
 Local/regional 1.00 - - 
 Metastatic 0.53 0.35, 0.81 0.003 
 All stages  1.28 0.96, 1.71 0.098 
Recruitment 
period in PSA 
era or earlier 
    
 Yes 0.89 0.69, 1.13 0.330 
 No 1.00 - - 
Study type     
 Randomized 
control trial 
1.18 0.84, 1.67 0.342 
 Retrospective 
cohort study 
1.00 - - 
*All P values are two-sided 
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Table 7. Listing of Studies using the SEER Registry Data 
No. Author and 
year 
Recruitment 
period 
Source Population 
characteristics 
1 Robbins et al 
(2000)16  
1973-1993 SEER - San 
Francisco Bay 
region  
All prostate 
cancer cases 
2 Polednak et 
al (2003)11  
1988-1997 9 SEER sites 
including Atlanta, 
Connecticut, 
Detroit, Hawaii, 
Iowa, New 
Mexico, San 
Francisco/Oakland, 
Seattle-Puget 
Sound and Utah 
Advanced 
prostate 
cancer cases 
3 Oakley-
Girvan et al 
(2003)22  
1987-1991 SEER – Hawaii, 
Los Angeles, San 
Francisco and 
Vancouver 
All prostate 
cancer cases 
4 Du et al 
(2006)10  
1992-1999 11 SEER sites 
including San 
Francisco/Oakland, 
Detroit, Atlanta, 
Seattle, Los 
Angeles county, 
San Jose-Monterey 
area, Connecticut, 
Iowa, New 
Mexico, Utah and 
Hawaii 
Local/regional 
stage prostate 
cancer cases 
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Figure 1. Flowchart of study selection criteria 
 
 Medline search 
“prostate cancer”, 
“survival”, “mortality” and 
“race” 
First level abstract search 
Race as the main exposure 
variable or at least one of 
the covariates and overall 
survival or cause-specific 
survival as one of the 
outcome variables 
 
Identified 505 
publications 
 
Identified 115 
abstracts 
 
Second level publication 
search  
Reviewed each publication 
to determine if it met the 
inclusion criteria, relevant 
estimates available and 
further reference search 
Identified 52 
publications  
Third level search 
One publication per study or 
dataset or location with 
relevant data 
Identified 20 
publications 
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Figure 2. Forest plot of studies with adjusted estimates for overall survival 
NOTE: Weights are from random effects analysis
Overall
StudyName
Freeman
Optenberg
Halabi
Thompson
Dayal
Du
Roach
Tewari
Year
2004
1995
2006
2001
1985
2006
2003
2006
1.07 (0.94, 1.22)
Ratio (95% CI)
1.75 (1.33, 2.30)
0.64 (0.40, 1.04)
0.77 (0.65, 0.92)
Hazard
1.23 (1.04, 1.46)
1.13 (0.96, 1.33)
1.01 (0.97, 1.06)
1.17 (0.96, 1.43)
1.02 (0.88, 1.19)
AA have lower mortality  AA have higher mortality 
1.397 2.52
 
Figure 3. Funnel plots of studies with unadjusted and adjusted estimates for overall 
survival 
Begg's funnel plot with pseudo 95% confidence limits
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Figure 4. Forest plot of studies with adjusted estimates for prostate cancer-specific 
survival 
NOTE: Weights are from random effects analysis
Overall
Du
Fowler
StudyName
Halabi
Tewari
Iselin
Roach
Freeman
2006
2000
Year
2006
2006
1998
2003
2004
1.15 (0.95, 1.40)
1.17 (0.99, 1.38)
1.23 (0.90, 1.68)
Ratio (95% CI)
0.76 (0.63, 0.92)
1.11 (0.87, 1.41)
1.22 (0.67, 2.21)
Hazard
1.26 (0.96, 1.66)
1.84 (1.22, 2.78)
AA have lower mortality  AA have higher mortality 
1.359 2.78
Figure 5. Funnel plots of studies with unadjusted and adjusted estimates for prostate 
cancer-specific survival 
        
Begg's funnel plot with pseudo 95% confidence limits
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CASE-CONTROL STUDY: ASSOCIATION BETWEEN FAMILY 
HISTORY OF CANCERS AND PROSTATE CANCER 
 
 
INTRODUCTION 
            Prostate cancer is the most common cancer among men in the United States. It 
accounts for about 25% of all the cancers diagnosed in men.1 Family history of prostate 
cancer is a well established risk factor for prostate cancer risk in men. Several 
prospective 2, 3, 4, 5 and retrospective6, 7, 8, 9, 10, 11, 12, 13 studies have reported a two to four- 
fold increased risk of prostate cancer in men with a positive family history of prostate 
cancer especially in a first-degree relative. 
 To date, three meta-analyses have confirmed the association between family 
history of prostate cancer and risk of prostate cancer in men. They consistently concluded 
that there was an increased risk of prostate cancer in men with affected first-degree 
family members; and the risk was greater for men with affected brother than affected 
father, increases with decreasing age of the patient and family members and increasing 
number of affected individuals in the family.14, 15, 16   
However there are only limited studies exploring the association between family 
history of other forms of cancers other than prostate cancer and risk of developing 
prostate cancer. Some studies have implicated family history of breast cancer as a risk 
factor for prostate cancer 6, 17, 18, 19, 20, 21, 22, 23, 24, 25 whereas others have not.2, 26, 27, 28, 29, 30  
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Similarly, a few studies have shown an association between family history of  colorectal 
cancer, 4, 22  ovarian cancer,31  kidney cancer,25, 31, 32, 33  stomach cancer,25, 34  esophageal 
cancer,28, 31 , bladder cancer,31 , brain cancer,35 , leukemia,35 , central nervous system,36   
and  prostate cancer risk in men. However, a number of studies have not found such an 
association with certain cancers.2, 6, 20, 26, 27, 28, 31, 35, 37  
 The major problem with existing corpus of literature was the inability of 
investigators to control for potential confounders. It was evident that some of these 
studies were only able to control for the effect of age and other studies were not able 
control for any of the potential confounding factors due to inadequate sample size. Small 
sample size and neglecting the impact of other demographic and lifestyle factors have 
had potential impact on the association. It is also important to note that some of these 
studies utilized cancer registry data to calculate the observed and expected incidence rates 
and examined the association between family history of different cancers and prostate 
cancer risk, which may not be accurate. The data in the cancer registries is obtained from 
hospital and medical records and only limited to information and accuracy available in 
those datasets. Additionally, it is important to note that most of the studies exploring 
family history of cancers and prostate cancer were conducted in countries other than the 
US.  The few studies conducted in the US predominantly focused on Caucasian 
population. 
In conclusion, the methodological limitations of the current body of literature are 
evident and require further investigation. This study proposes to investigate the 
association between family history of cancers and risk of prostate cancer in a 
heterogeneous population in Central Virginia. 
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MATERIALS AND METHODS 
Study design 
 The study sample included 3,710 patients from a large, multi-site private urology 
practice located in Central Virginia. Cases were a random sample of 1,237 patients with 
histologically confirmed diagnosis of prostate cancer. This included prostate cancers of 
all stages and grades diagnosed from January 2000 to December 2005. Controls were a 
random sample of 2,473 patients who visited the clinic during the same time as the cases 
and were diagnosed with urological illnesses other than cancers and prostate-related 
problems including prostatitis and chronic prostate hypertrophy. Patients with prostate-
related problems or any urological cancer were excluded to reduce misclassification bias. 
Furthermore, chronic prostatitis and benign prostate hypertrophy were not included 
because of the potential link with excess risk of prostate cancer.38, 39, 40 Additionally, this 
study excluded patients diagnosed before January 2000 and after December 2005, who 
were non-English speaking and unable to complete the questionnaire due to mental or 
cognitive problems. 
Data collection 
 A mail survey was conducted to collect data on family history of cancers, life 
style behaviors and demographic information. Data included family history of cancers, 
age, race, education, employment, income, marital history, height, weight, behavioral risk 
factors such as diet history, sunlight exposure, smoking habits, alcohol use, physical 
activity, STD history and history of vasectomy. The survey included validated questions 
from the BRFSS,41, 42, 43  NHIS,44  NHANES,45  Family history survey, 46 and Nurses’ 
health study47  surveys. Information on family history of cancers was obtained using the 
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family history table from Quillin et al.46   The question asked to complete a family history 
table and indicate if there were family members diagnosed with cancers, their 
relationship with the patient, the type of cancer, age at diagnosis, the side of the family 
(maternal or paternal) and if they died from the cancer. 
 The survey was conducted after the questionnaire was pre-tested and approved by 
the institutional review board. The mail survey utilized the method suggested by 
Dillman.48 First, a brief pre-notice postcard was mailed in first class mail to the selected 
3,510 participants. Four weeks after the pre-notice postcard, the questionnaire was mailed 
to 3,490 participants after excluding those who did not want to be contacted (n=4) and 
deceased (n=16). Five days after the questionnaire was mailed, a thank-you letter was 
sent to 3,271 participants after removing those who did not want to be contacted (n=2), 
deceased (n=2) and wrong addresses without forwarding addresses (n=215). Two weeks 
after the thank-you letter, a replacement questionnaire was mailed to 2,219 non-
responders as a reminder to complete the survey after excluding deceased (n=57), those 
who did not want to participate (n=37), valid surveys returned (n=862), wrong addresses 
(n=68) and other reasons (n=28). This mailing methodology yielded an overall 37% 
response rate; a total sample size of 1,286 participants (600 cases and 686 controls). 
Definitions of variables 
     Patient status, having prostate cancer (case) and no prostate cancer (control) 
served as the outcome variable. The main exposure variable family history of cancers was 
defined as self-reported history of cancers including prostate, breast, colon, lung, skin, 
digestive tract, stomach, liver, pancreas, female cancers, urogenital, urinary bladder, 
brain, blood and lymph node and other cancers among first-degree relatives including 
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parents, siblings or offspring and also parents and siblings separately. Other covariates 
including BMI (<25 kg/m2, 25-29.99 kg/m2, ≥30 kg/m2), physical activity (0 days per 
week, 1-2 days per week, ≥3 days per week), alcohol consumption (0 drinks per day, 1-2 
drinks per day, ≥3 drinks per day), smoking (non-smoker, former smoker, current 
smoker), diet including fruits and vegetables intake (<2 servings per day, 2-4 servings per 
day, >4 servings per day), milk consumption (never, at least once per week, ≥1 time per 
day), vitamin intake (yes, no), history of vasectomy (yes, no) and STD (yes, no), age 
(≤60, 61-70, >70), race (White, African American, Hispanic, Other), marital status 
(married, divorced, never married), education (less than grade 12, grade 12 or GED, some 
college, college graduate) and income (less than $25,000, $25,000 to less than $50,000, 
$50,000 to less than $75,000, $75,000 to less than $100,000, $100,000 or more) were 
collected. 
Statistical analysis 
 A descriptive analysis was done to examine the distribution of the study 
participants and assess the comparability of cases and controls. Chi square test and p-
values were calculated to examine the association between categorical variables.  
 Univariate analysis was conducted using the main exposure variable and other 
covariates. The association between family history of any cancer and cancer at each 
location including prostate, breast, colon, lung, skin, digestive tract, stomach, liver, 
pancreas, female cancers, urogenital, urinary bladder, brain, blood and lymph node and 
other cancers in first-degree relatives, parents and siblings alone and risk of developing 
prostate cancer in men were estimated using unconditional logistic regression. First-
degree relatives were defined as parents, siblings or off-springs. Odds ratios and 
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corresponding 95% confidence intervals were determined in the multivariate analysis 
after accounting for the potential confounding variables. Multiple comparisons 
adjustments were made using Bonferroni adjustment. All the analysis was conducted in 
SAS version 9.1 and all the tests were two-sided. Comparison between responders and 
non-responders would be appropriate; however, information on non-responders was not 
available. 
RESULTS 
The study sample included 600 cases (47%) and 686 controls (53%). Cases were 
more likely to be older than controls but less likely to be college educated and have high 
income (Table 1). Cases and controls were similar in marital status and race distribution. 
About 52.4% of the cases were over 70 years old compared to 12.4% in the controls. 
Cases had about 45% college educated and 22% with some college education compared 
to 46% and 26% in controls respectively. More cases had less than high school education 
(14% compared to 6% in controls). One-fourth of the cases made over $100,000 per years 
compared to 35% among controls. Over 40% of the cases made less than $50,000 per 
year compared to 25% of the controls. Both cases and controls had over 80% Whites, 
about 10% African Americans, over 80% married and about 15% divorced. 
 In the crude analysis, compared to men with no family history of cancers, those 
who have family history of any cancer in first-degree relatives were 1.8 times more likely 
to develop prostate cancer (Table 2). An increased risk was also observed with history of 
cancers in siblings. Compared to men with no family history of cancers, those who have 
family history of any cancer in siblings were 2.6 times respectively more likely to 
develop prostate cancer. Significant increased risk was also shown with family history of 
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prostate cancer in first-degree relatives, only parents and siblings compared to men with 
no family history of prostate cancer. Compared to men with no family history of lung 
cancer, men with a family history of lung cancer in siblings were at increased prostate 
cancer risk (OR=4.56, 95% CI: 1.95, 10.68). There was a significant protective effect 
observed with family history of skin cancer in first-degree relatives (OR=0.55, 95% CI: 
0.32, 0.94) and just parents (OR=0.47, 95% CI: 0.25, 0.91) compared to men with no 
family history of skin cancer.  
Adjusted analysis confirmed that men with family history of any cancer in first-
degree relatives were 2.42 times more likely to develop prostate cancer (OR=2.42, 95% 
CI: 1.53, 3.84) compared to men with no family history of cancers (Table 2). Men with 
family history of any cancer in parents alone were 1.90 times more likely to develop 
prostate cancer (OR=1.90, 95% CI: 1.23, 2.94) compared to men with no family history 
of cancers. Significant increased risk was observed with family history of prostate cancer 
in first-degree relatives (OR=2.68, 95% CI: 1.53, 4.69) and only parents (OR=3.26, 95% 
CI: 1.71, 6.24) compared to men with no family history of prostate cancer. Even after 
adjustments for multiple comparisons, there was a statistically significant increased risk 
among men with family history of prostate cancer in first-degree relatives (OR=2.68, 
95% CI: 1.16, 6.21) and parents alone (OR=3.26, 95% CI: 1.24, 8.63) compared to men 
with no family history of prostate cancer. Men who have a family history of brain cancer 
in first-degree relatives were 9.09 times more likely to develop prostate cancer (OR=9.09, 
95% CI: 1.48, 55.96) compared to men with no family history of brain cancer. This 
association lost its statistical significance when adjustments were made for multiple 
comparisons (OR=9.09, 95% CI: 0.60, 138.64) (Table 2). 
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DISCUSSION 
This study showed that there was increased prostate cancer risk associated with 
family history of any cancer in first-degree relatives. Specifically men with family history 
of any cancer only in parents were two times more likely to develop prostate cancer. This 
is similar to the observation in the population-based case-control study conducted at 
Shanghai, China where a 1.79 times increased prostate cancer risk was reported with any 
type of cancer in first-degree relatives (OR=1.79, 95% CI: 1.21, 2.63) and 2.21 times 
increased risk was observed with any type of cancer in only parents compared to no 
family history of any cancer (OR=2.21, 95% CI: 1.31, 3.73).28  Negri et al. also reported 
that family history of cancer at all sites (OR=1.5, 95% CI: 1.3, 1.8) and family history of 
cancer at all sites excluding prostate cancer (OR=1.3, 95% CI: 1.1, 1.6) in first-degree 
relatives was associated with an increased risk of prostate cancer.31  On the other hand, a 
case-control study conducted in Italy showed 1.6 times increased risk with family history 
of cancer in all sites in first-degree relatives (OR=1.6, 95% CI: 1.2, 2.3)  but reported no 
statistically significant risk with family history of cancer in all sites excluding prostate 
cancer in first-degree relatives (OR=1.2, 95% CI: 0.8, 1.7).35  
Consistent with the past literature 2, 6, 17, 19, 20, 26, 27, 29, 30, 31, 35 this study showed a 
two fold increased risk of prostate cancer among men with family history of prostate 
cancer in first-degree relatives and three fold increased risk for those with family history 
of prostate cancer in only parents. This significance persisted even after adjusting for 
multiple comparisons. 
This study concluded that men who have a family history of brain cancer in first-
degree relatives were 9.09 times more likely to develop prostate cancer. This finding is 
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similar to the conclusions made by the case-control study conducted in Italy in 2007 
among men 60 years or less.35  They found that men with family history of brain cancer 
in first-degree relatives were 3.7 times more likely to develop prostate cancer (OR=3.7, 
95% CI: 1.2, 11.7). The current study found a stronger association and this could be 
explained by the fact that Gallus et al. study had 8 cases and 6 controls with family 
history of brain cancer compared to 13 cases and 5 controls with family history of brain 
cancer in the present study. This result has to be interpreted with caution due to small cell 
sizes, wide confidence intervals and multiple comparisons. Small changes in the cell sizes 
can drastically change the estimates. It is important to note that the statistical significance 
was lost after adjustment for multiple comparisons. So the association that we observed 
may be due to chance. But studies have shown that Li-fraumeni syndrome occurring in 
young patients with an aggregation of cancers including brain tumor, leukemia, 
adrenocortical carcinoma, breast cancer and sarcoma could occasionally be accompanied 
by prostate cancer and this is attributed to germline mutation in p53.20  Future large 
prospective studies with larger cell sizes and adequate control for potential confounders 
are needed to confirm is this association is due to chance or if there is a genetic 
component and co-clustering with other cancers. 
There was a non-statistically significant decreased risk associated with skin 
cancer in the unadjusted analysis both among first-degree relatives (OR=0.55, 95% CI: 
0.32, 0.94) and just parents (OR=0.47, 95% CI: 0.25, 0.91) that disappeared after 
adjusting for potential confounders. This finding has never been shown or explored in 
any other studies before. Many studies exclude skin cancers which may be due to the 
reason that skin cancer is underreported as reporting is not mandatory except for 
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melanoma and skin cancer is the most common and curable cancer. This result could be 
due to chance but should be explored further in future studies or could be due to shared 
genetic factors.  
The current study found non-significant increased risk with family history of 
cancers including breast, colon, lung, digestive tract, pancreas, female cancers, 
urogenital, bladder and blood and lymph node. Linkage studies have shown co-clustering 
between prostate cancer, breast, ovarian and colon cancer due to BRCA 1 and 2 genes in 
the chromosome 17q.49, 50 But our study did not find an association between family 
history of breast, ovarian and colon cancer and prostate cancer. This could be due to 
extensive control for potential confounders. 
This study found non-significant decreased risk with stomach and liver cancers 
both in first-degree relatives and parents alone. In contrast, past studies have shown non-
significant increased risk associated with stomach and liver cancer both in first-degree 
relatives and parents alone.28, 31 This difference noted may be due to extensive control for 
confounders in the present study but there are no apparent biological explanations 
available for this finding. 
Knowledge of family history of cancers is very important. It helps distinguish 
between the hereditary and sporadic cancers that have some key differences. A review 
article by Bratt et al. in 2002 examined the differences in clinical characteristics between 
hereditary and sporadic prostate cancer.55  They found that one major difference between 
the hereditary and sporadic cancer is that hereditary prostate cancer is diagnosed at least 6 
or 7 years earlier than sporadic cancer.55  But hereditary and sporadic prostate cancers do 
not have any differences in tumor grade or pathological stage at diagnosis.56, 57, 58, 59  
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Studies have shown mixed findings with differences in outcomes between hereditary and 
sporadic cancers 57, 59, 60, 61 As a result of early diagnosis, more men with hereditary 
prostate cancer tend to die due to the disease.55  This difference calls for early screening 
in men with family history of cancer specifically prostate cancer and other cancers. A 
recent US randomized control trial, Prostate, Lung, Colorectal and Ovarian cancer 
screening study 62 reported that routine PSA screening has no effect in reducing the rate 
of death from prostate cancer. However, a European randomized study on prostate cancer 
screening 63 concluded that there was a decrease in death rate due to prostate cancer by 
20% but there was an increased risk of overdiagnosis. Therefore PSA screening may not 
be mandatory and necessary in sporadic prostate cancers. However, in the case of 
hereditary prostate cancer, early PSA screening may be necessary so that the cancer can 
be diagnosed and treated at early stages and grades. But it is necessary to conduct 
randomized control trials to confirm that early diagnosis and treatment of hereditary 
prostate cancers improves survival and quality of life. To determine if a patient has a 
hereditary or sporadic prostate cancer, knowledge of family history of cancers is very 
crucial. 
Potential strengths of this study include good response rate to mail surveys, 
extensive collection of data and control of known and potential confounders, thorough 
exploration of family history of several cancers on prostate cancer risk and adjusting for 
multiple comparisons in the analysis. This study collected and controlled for extensive 
list of known and potential confounders and controlled for them in the data analysis. Past 
studies had controlled either only for age or had a partial control for confounders. This 
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could have partly played a role in past studies showing more statistically significant 
results. 2, 19, 20, 28, 31, 35, 37   
Limitations include that there may have been a problem of misclassification of the 
family history as it is based on self-reported data. No additional validation of the self-
reported information was conducted. However, past studies have shown that self-reported 
family history data can be accurate. Two studies from Sweden and US have shown that 
self-reported family history of prostate cancer in prostate cancer cases have an accuracy 
of 92% and 86% respectively. King et al. also found accuracy of self-reported family 
history with other cancers- 95% for breast cancer, 92% for colon cancer, 100% for 
bladder and kidney cancer and 82% for all sites.51, 52, 53, 54 Considering the design of this 
study, it is possible that the cases over reported and the controls under reported the 
exposure resulting in overestimation of the association. The crude estimate was 
calculated using the proportions of family history of prostate cancer in cases and controls 
from a meta-analysis by Bruner et al. This yielded estimate similar to the estimate 
obtained in the current study.15  
Another inherent problem with case-control study is recall bias as cases may 
recall family history of cancers different than the controls. This could overestimate our 
results. This study used clinic controls and they may be different from the general 
population controls. It is possible that the cases and controls may share common risk 
factors and this may underestimate the association. Since the cases were selected from 
this clinic, it is a preferred population to select the controls from the same clinic to be 
comparable. But patients with any urological cancer and prostate-related problem were 
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excluded and controls were selected from a variety of diagnosis to reduce 
misclassification of controls.  
This study was done in a private urology clinic and majority of the cases may 
more have been referred to this clinic. This makes the cases different from the control 
population and may overestimate the association. However, differential referral patterns 
between cases and controls were not expected since the study participants were urology 
patients. The mail survey obtained an overall 37% response but a 53% response rate 
among cases and 29% among controls. If the non-responders are systematically different 
from the responders, this can overestimate or underestimate the association. It is possible 
that cases or those with family history of cancers may be more willing to respond than the 
controls or those without the risk factor; resulting in underestimation of the association. 
However, information on non-responders was not available in this study to assess 
comparability of non-responders with responders. 
The current study showed that there is an increased risk of prostate cancer for men 
with a family history of any cancer and prostate cancer in first-degree relatives and 
parents alone. But the association between family history of other cancers and prostate 
cancer risk was not statistically significant. Future studies should be conducted to explore 
the association between family history of other cancers and prostate cancer risk in a large 
prospective follow-up study accounting for known and potential confounders. 
Additionally, future studies should examine the genetic and shared environmental 
influences associated with prostate cancer risk. This is important as the hereditary and 
sporadic cancers behave differently in terms of mortality. Knowledge of family history of 
cancers is very important to differentiate hereditary and sporadic cancers. Health care 
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practitioners need to be educated about the importance of family history of cancers so 
that this information can be routinely collected. 
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Table 1: Distribution of the study characteristics 
 
 Cases (%) Controls (%) 
Age (Years)   
≤60 70 (13.2) 375 (59.7) 
61-70 183 (34.4) 175 (27.9) 
>70 279 (52.4) 78 (12.4) 
Race   
White 474 (81.0) 563 (83.0) 
African American 63 (10.8) 63 (9.3) 
Hispanic  40 (6.8) 33 (4.9) 
Other 8 (1.4) 19 (2.8) 
Marital status   
Married 498 (83.7) 557 (82.0) 
Divorced 90 (15.1) 95 (14.0) 
Never Married 7 (1.2) 27 (4.0) 
Education   
<Grade 12  80 (13.8) 41 (6.2) 
Grade 12 or GED 113 (19.5) 147 (22.2) 
Some college  126 (21.8) 172 (26.0) 
College graduate 260 (44.9) 301 (45.5) 
Household income   
< $25,000 69 (14.0) 55 (9.0) 
$25,000 to < $50,000 132 (26.8) 107 (17.5) 
$50,000 to < $75,000 95 (19.3) 134 (21.9) 
$75,000 to < $100,000 74 (15.0) 100 (16.4) 
≥ $100,000 123 (25.0) 215 (35.2) 
BMI   
≤24.99 178 (30.5) 145 (21.6) 
25-29.99 281 (48.2) 302 (44.9) 
≥30 124 (21.3) 226 (33.6) 
Moderate activity (in days per 
week) 
  
0 82 (15.1) 106 (16.6) 
1-2 86 (15.8) 124 (19.4) 
≥3 377 (69.2) 408 (64.0) 
Alcohol (drinks per day)   
0 203 (39.1) 174 (28.8) 
1-2 285 (54.9) 391 (64.6) 
≥3 31 (6.0) 40 (6.6) 
Smoking   
Current smoker 43 (7.2) 87 (12.7)  
Former smoker 62 (10.3) 46 (6.7) 
Non-smoker 495 (82.5) 553 (80.6) 
Fruits and Vegetables (servings per 
day) 
  
<2 145 (25.3) 208 (31.1) 
2-4 264 (46.1) 305 (45.6) 
>4 164 (28.6) 156 (23.3) 
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 Cases (%) Controls (%) 
Milk (servings) 
Never 52 (9.0) 60 (9.2) 
At least 1 time per week 328 (57.0) 397 (61.2) 
≥1 time per day 195 (33.9) 192 (29.6) 
Vitamin intake   
Yes 390 (66.0) 418 (61.8) 
No 201 (34.0) 258 (38.2) 
Vasectomy   
Yes 155 (27.4) 193 (29.0) 
No 411 (72.6) 473 (71.0) 
STD   
Yes 50 (8.6) 84 (12.4) 
No 530 (91.4) 592 (87.6) 
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CASE-CONTROL STUDY: ASSOCIATION BETWEEN OBESITY 
AND PROSTATE CANCER 
 
 
INTRODUCTION 
 Obesity is a major public health problem in the United States and affects over 
30% of the adult population. The prevalence of obesity in adults has continued to 
increase over the past several decades. The recent 2003-04 data published by the National 
Health and Nutrition Examination Survey (NHANES), which measured height and 
weight from 4,431 adults, showed that 32.2% of the adult population in the US was 
obese.1   
 Disease conditions including diabetes, hypertension, high cholesterol, asthma, 
arthritis and poor health status are associated with obesity.2 Furthermore, prospective 
studies have shown that there is increased risk of death due to cardiovascular disease and 
several cancers including prostate cancer in men who are obese.3, 4, 5 Prostate cancer is the 
most common malignant neoplasm in men. In 2008 alone, approximately 186,320 new 
cases were estimated to be diagnosed in the United States.6 Several studies have explored 
the association between obesity and risk of developing prostate cancer in men. These 
studies have shown mixed findings between higher BMI and prostate cancer risk.  
 The most recent prospective study using over 280,000 men who participated in 
the NIH-AARP diet and health study showed significant decreased risk with localized 
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prostate cancer for men with BMI ≥40 kg/m2 compared to men in lower BMI category 
<25 kg/m2 (RR=0.67, 95% CI: 0.50, 0.89) and extraprostatic disease with BMI 35-39.9 
kg/m2 compared to men in lower BMI category <25 kg/m2 (RR=0.68, 95% CI: 0.49, 
0.94).7  Similarly, the prospective study using the cohort of 50,000 men from the Health 
Professionals follow-up study found that men with high BMI of ≥ 30kg/m2 compared to 
men in normal BMI category 23-24.9 kg/m2 had lower risk of developing prostate cancer 
among those who were less than 60 years old (RR=0.52, 95% CI: 0.33, 0.83) or had a 
family history of prostate cancer (RR=0.74, 95% CI: 0.45, 1.19).8   
 A meta-analysis looking at 31 cohort studies and 25 case-control studies from 
1966 to 2004 found that obesity was weakly associated with prostate cancer (RR=1.05 
per 5 kg/m2 increment, 95% CI: 1.01, 1.08). There was increased risk observed with 
advanced disease (RR=1.12 per 5 kg/m2 increment, 95% CI: 1.01, 1.23) and decreased 
risk with localized disease (RR=0.96 per 5 kg/m2 increment, 95% CI: 0.89, 1.03).9  A 
large Swedish retrospective cohort study conducted on 135,000 construction workers 
with an average of 18 years follow-up also showed a non-significant positive association 
between prostate cancer risk and weight, height, BMI >26.2 kg/m2  (RR=1.13, 95% CI: 
0.99, 1.29) compared to BMI <22.1 kg/m2  and lean body mass. The association was 
stronger for prostate cancer mortality than prostate cancer incidence.10 Several other 
studies have shown that obesity increases the risk of developing prostate cancer.11, 12, 13, 14, 
15      
 In contrast, numerous studies have shown that there is no association between 
obesity and risk of prostate cancer.16, 17, 18, 19, 20, 21, 22, 23, 24, 25  Furthermore, a report from 
the Baltimore longitudinal study of aging revealed that greater waist to hip ratio was 
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associated with an increased but not statistically significant risk for prostate cancer both 
in age-adjusted and multivariate analysis adjusted for age, smoking and fasting insulin.26  
The Netherlands cohort study that followed over 58,000 men for 6.3 years also found no 
association between BMI and development of prostate cancer.27  The Health Professionals 
study in the US also assessed the relationship between anthropometric measurements and 
prostate cancer risk on 47,781 men. The study showed that adult BMI, and hip and waist 
circumferences were not associated with risk of total or advanced prostate cancer.28   
 Recent studies have show that higher BMI is associated with increased risk of 
advanced prostate cancer and has a protective effect on localized early prostate cancer. A 
prospective study from the Cancer Prevention Study II cohort found that BMI ≥ 35kg/m2 
was inversely associated with risk of non-metastatic low-grade prostate cancer (RR=0.84, 
95% CI: 0.66, 1.06) compared to BMI <25kg/m2. It further found that BMI 30-<35kg/m2 
compared to BMI <25kg/m2 was positively associated with risk of non-metastatic high-
grade prostate cancer (RR=1.22, 95% CI: 0.96, 1.55) and metastatic and fatal prostate 
cancer (RR=1.54, 95% CI: 1.06, 2.23).29  Another study from the Prostate cancer 
prevention trial found that obese men with BMI ≥ 30kg/m2 compared to BMI <25kg/m2 
had an 18% decreased risk of low grade prostate cancer (RR=0.82, 95% CI: 0.69, 0.98) 
and 29% increased risk of high grade prostate cancer (RR=1.29, 95% CI: 1.01, 1.67).30   
 Majority of these studies have looked at obesity in late adult life either before 
cancer diagnosis or study onset. It is important to examine the effects of obesity in early 
childhood and adulthood on prostate cancer risk to determine the true association before 
the cancer process has begun. Studying obesity in late adult life during study onset or 
before cancer diagnosis may not be a true indicator as the cancerous conversion may have 
   
 59 
already started. To our knowledge, there is only one recent systematic review and meta-
analysis that studied the association between early-adult obesity and prostate cancer risk. 
Robinson et al. analyzed nine cohort and seven case-control studies that explored the 
association between early-adult BMI and prostate cancer risk. They showed that there 
was non-significant increased prostate cancer risk associated with five-unit increase in 
early-adult BMI (RR=1.06, 95% CI: 0.99, 1.14). Additionally, this study showed limited 
evidence of protective effect between early-adult obesity and advanced prostate cancer 
but not with localized cancer.31   
Compared to the wealth of literature examining obesity before cancer diagnosis or 
at the time of study entry and prostate cancer risk, the studies addressing early-onset 
obesity and prostate cancer risk are limited. Only a few studies as addressed in the meta-
analysis by Robinson et al. have looked at early-onset obesity and prostate cancer risk.31 
Some of these studies looking at early-onset obesity showed increased risk of prostate 
cancer 13, 16, 18, 22, 23, 27, 32, 33 whereas others showed decreased risk.7, 28, 34, 35 The scant 
literature in this area has also presented several methodological problems. Most of these 
studies have examined BMI only as a categorical variable with inconsistent definitions 
and cut-off points. The inconsistency in the definition of obesity has made comparability 
of these studies very difficult. Although most studies have used BMI to determine 
obesity, studies have categorized obesity into different ranges disregarding the standard 
and internationally accepted World Health Organization (WHO) categories. Another 
limitation of these studies is also the poor and inconsistent control of confounders with 
some studies only controlling for age. There is no adequate control for individual level 
demographic, behavioral and clinical factors. Therefore the current study investigated the 
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relationship between early-onset obesity, current obesity and prostate cancer risk 
controlling for known and postulated confounding factors, utilizing the widely accepted 
WHO definitions for categorizing BMI. This study also evaluated BMI both as 
categorical and continuous variable.  
MATERIALS AND METHODS 
Study design 
 This study used data from a case-control study conducted in Central Virginia 
between September and October 2008. The study was designed to examine the influence 
of obesity, lifestyle behaviors and demographic factors on prostate cancer. 
Study setting and population 
 Potential study participants (N=3,710) were recruited from a private urology 
practice that consists of nine clinics serving Central Virginia. Cases (N=1,237) were 
randomly selected from histologically confirmed prostate cancer patients of all stages and 
grades diagnosed from January 2000 to December 2005. Controls included a random 
sample of 2,473 urologic patients other than cancers and prostate-related problems who 
were diagnosed during the same time period. This study excluded patients diagnosed 
before January 2000 and after December 2005, non-English speaking and those with 
mental and cognitive problems who cannot complete the questionnaire. 
Data collection   
 Before the beginning of the study, data collection instrument was pre-tested and 
necessary adjustments were made. To enhance the response rate, this study used the 
Dillman mail survey methodology.36 The survey procedure included a series of mailings 
including a pre-notice postcard, questionnaire, thank-you letter and a replacement 
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questionnaire. Initially a pre-notice postcard was mailed to 3,510 potential study 
participants informing them the intent of the study. The questionnaire accompanied by a 
cover letter and a return envelope was mailed following the pre-notice postcard. A thank-
you letter was then sent to 3,271 participants after removing the deceased, wrong 
addresses and those who did not want to be contacted. Two weeks after the thank-you 
letter, 2,219 participants were sent with a final reminder and replacement questionnaire. 
Overall a 37% response rate was obtained and 1,286 (600 cases and 686 controls) valid 
questionnaires were collected. Adequate information was not available on the non-
responders and therefore comparison between responders and non-responders was not 
done. 
Measurement of covariates 
            Validated questions from the BRFSS,37, 38, 39  NHIS,40  NHANES,41  Family 
history survey,42  and Nurses’ health study43  surveys were adopted. Data on current 
height, weight and weight at age 18 were collected. Lifestyle factors such as diet history, 
sunlight exposure, smoking habits, alcohol use, physical activity, STD history and history 
of vasectomy and demographic information including age, race, education, employment, 
income, marital status were also collected. Relevant questions to collect all the necessary 
information on lifestyle and demographic factors were not available in one standardized 
questionnaire. Therefore appropriate questions were selected from several validated 
questionnaires, combined and used in the mail survey.  
 The main outcome variable for this study was patient status (cases and controls). 
Cases were prostate cancer patients regardless of the stage and severity of the disease. 
Controls were patients who visited the clinic for urological problems other than cancers 
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and prostate problems. The main exposure variable obesity was depicted by BMI, defined 
as weight (in kilograms) divided by square of the height (in meters). BMI was 
categorized in accordance to the World Health Organization classification as, normal 
(BMI less than 25kg/m2), overweight (BMI 25-29.9 kg/m2) and obese (BMI >=30 
kg/m2).44  Covariates such as, physical activity (0 days per week, 1-2 days per week, ≥3 
days per week), alcohol consumption (0 drinks per day, 1-2 drinks per day, ≥3 drinks per 
day), smoking (non-smoker, former smoker, current smoker), diet including fruits and 
vegetables intake (<2 servings per day, 2-4 servings per day, >4 servings per day), milk 
consumption (never, at least once per week, ≥1 time per day), vitamin intake (yes, no), 
history of vasectomy (yes, no) and STD (yes, no), age (≤60, 61-70, >70), race (White, 
African American, Hispanic, Other), marital status (married, divorced, never married), 
education (less than grade 12, grade 12 or GED, some college, college graduate) and 
income (less than $25,000, $25,000 to less than $50,000, $50,000 to less than $75,000, 
$75,000 to less than $100,000, $100,000 or more) were examined. 
Statistical analysis 
 The association between BMI and risk of developing prostate cancer were 
estimated using unconditional logistic regression. Univariate analysis was done using the 
main exposure variable and other covariates. Four unconditional multiple logistic 
regression models were built to examine the associations between prostate cancer and 
BMI. BMI at age 18 and current BMI was examined both as categorical and continuous 
variable. Interaction effects were assessed using the likelihood ratio test and then 
potential confounders were assessed using the 10% change in estimate rule. Odds ratios 
and corresponding 95% confidence intervals were determined after accounting for 
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potential interactions and adjusting for the potential confounding variables. Data analysis 
was performed in SAS version 9.1 and all the statistical tests were two-sided.  
RESULTS 
Distribution of the study characteristics 
The demographic and characteristics of the population are described in Table 1. 
Majority of the men were white (82.1%), married (82.8%), college graduate (45.2%) or 
have completed some college (24.0%). About half the participants earn $75,000 or more 
per year (46.4%). About 81% of the men were normal weight at age 18 whereas 46% of 
them were overweight and 28% obese at present. Cases were more likely to be older than 
controls but less likely to college educated and have high income. They are both similar 
in race and marital status distributions. 
BMI at age 18 
The crude analysis showed that being overweight at age 18 had a significant 
protective effect on prostate cancer risk. Overweight men at age 18 had a 39% decreased 
risk of prostate cancer (OR=0.61, 95% CI: 0.44, 0.84) compared to normal weight men. 
On the other hand, obese men had a 43% decreased risk compared to normal weight men; 
however, this association was not statistically significant (OR=0.57, 95% CI: 0.24, 1.35). 
Test for trend showed a statistically significant trend associated with increasing BMI and 
decreasing prostate cancer risk (P = 0.002).  
A statistically significant decreased risk of prostate cancer was also observed 
when BMI was analyzed as a continuous variable. Per unit increase in BMI, there was 
6% reduced odds of prostate cancer risk (OR=0.94, 95% CI: 0.91, 0.97). Additionally, a 
statistically significant association was observed between family history of prostate 
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cancer and risk of developing prostate cancer in men (OR=2.76, 95% CI: 2.05, 3.72) 
compared to men with no family history of prostate cancer. Increasing age had a 
significant increased prostate cancer risk (Table 2). 
When the effect of potential confounders was controlled, BMI at age 18 remained 
significant. There was a 7% decrease in the odds of developing prostate cancer for every 
unit increase in BMI (OR=0.93, 95% CI: 0.87, 0.98) (Table 2). However, the association 
lost its statistical significance when BMI at age 18 was analyzed as a categorical variable. 
Although not statistically significant the direction of association remained the same; 
showing that overweight men at age 18 (OR=0.60, 95% CI: 0.35, 1.05) and obese men at 
age 18 (OR=0.62, 95% CI: 0.12, 3.08) had a non-significant decreased risk of developing 
prostate cancer compared to normal weight men.  
Family history of prostate cancer remained statistically significant in the adjusted 
analysis both when BMI at age 18 was treated as categorical and continuous variable. 
Compared to men with no family history, men with a family history of prostate cancer 
were 2.85 times more likely to develop prostate cancer (OR=2.85, 95% CI: 1.77, 4.58). 
Similarly, when BMI at age 18 was analyzed as continuous variable, there was increased 
prostate cancer risk associated with family history of prostate cancer compared to no 
history of prostate cancer (OR=2.99, 95% CI: 1.91, 4.69). There was a statistically 
significant association between age and risk of developing prostate cancer. Men who 
were between 61-70 years old were 8.52 times more likely to develop prostate cancer 
(OR=8.52, 95% CI: 5.23, 13.88) compared to men 60 years old or younger. Similarly, 
men 70 years and over had an increased risk of prostate cancer (OR=23.82, 95% CI: 
13.67, 41.51) compared to men 60 years or younger (Table 2). 
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Current BMI 
There was a statistically significant association between currently obese men and 
prostate cancer in the unadjusted analysis. Currently obese men were 0.45 times less 
likely to develop prostate cancer compared to normal weight men (OR=0.45, 95% CI: 
0.33, 0.61) whereas currently overweight men were 0.76 times less likely to develop 
prostate cancer though not statistically significant (OR=0.76, 95% CI: 0.58, 1.00) 
compared to normal weight men. There was an evident trend of decreasing risk of 
prostate cancer with increasing BMI (P<.0001). There was statistically significant 
decreased risk in prostate cancer for a unit increase in BMI when evaluated as a 
continuous variable (OR=0.94, 95% CI: 0.92, 0.96) (Table 2). 
Adjusted analysis showed that there was a non-significant decreased prostate 
cancer risk for a unit increase in BMI (OR=0.97, 95% CI: 0.92, 1.02) when BMI was 
analyzed as a continuous variable (Table 2). When BMI was examined as a categorical 
variable, there was a significant interaction between current BMI and age. Among men 
aged 60 years or less, overweight men had an increased risk of developing prostate 
cancer compared to normal weight men (OR=1.01, 95% CI: 0.59, 1.74) and obese men 
had a decreased risk (OR=0.73, 95% CI: 0.38, 1.40) compared to normal weight men, 
though not statistically significant. In the 61-70 years old age category, both overweight 
men (OR=0.73, 95% CI: 0.34, 1.57) and obese men (OR=0.44, 95% CI: 0.18, 1.10) were 
less likely to develop prostate cancer compared to normal weight men. This association 
was also not statistically significant. Similar relationship was observed in men over 70 
years with overweight (OR=0.71, 95% CI: 0.27, 1.87) and obese men (OR=0.74, 95% CI: 
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0.22, 2.56) having decreased prostate cancer risk compared to normal weight men (Table 
3 and Figure 1). 
Increased prostate cancer risk was evident with having a family history of prostate 
cancer compared to no family history and increasing age both when BMI was evaluated 
and categorical and continuous variable. Additionally, there was a two fold increased risk 
of prostate cancer in African American men compared to White men when BMI was 
analyzed as a continuous variable (OR=2.39, 95% CI: 1.15, 4.94) (Table 2). 
DISCUSSION 
This study showed that there was statistically significant decreased prostate 
cancer risk associated with increasing BMI at age 18 when evaluated as a continuous 
variable. To our knowledge, there were only two other studies examining BMI as a 
continuous variable to define early-onset obesity and risk of prostate cancer. Andersson 
et al. in 1995 conducted a case-control study among men under 80 years born in Sweden 
and found that there was no association between unit increase in BMI at age 20 and 
prostate cancer risk (OR=1.0 per 5 kg/m2 increment, 95% CI: 0.6, 1.5). But this analysis 
only adjusted for age, grade of urbanization and adult farming.45 The Netherlands cohort 
study examined association between BMI at age 20 and risk of developing prostate 
cancer. They found that there was a increase in the odds of prostate cancer risk by 1.08 
for every 2 kg/m2 increase in BMI though not statistically significant (RR=1.08 per 2 
kg/m2 increment,  95% CI: 0.99, 1.18). This study only adjusted for age, family history of 
prostate cancer and socioeconomic status.27 The inconsistency observed between this 
study and the studies in Sweden and Netherlands could be due to the inconsistencies in 
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the control of potential confounding factors. The current study has evaluated and 
controlled for an extensive number of potential confounding factors. 
This study found a non-statistically significant decreased risk of developing 
prostate cancer in both overweight and obese men at age 18 when BMI was categorized. 
These findings are similar to the results from the most recent prospective study that used 
over 280,000 men who participated in the NIH-AARP study that showed non-significant 
decreased risk with BMI ≥25 kg/m2 at age 18 (RR=0.93, 95% CI: 0.84, 1.02) but there 
was a trend of increased risk with extraprostatic cancer (RR=1.15, 95% CI: 0.90, 1.47) 
and decreased risk with localized cancer (RR=0.89, 95% CI: 0.80, 0.99) compared to 
BMI <18.5 kg/m2.7  A population-based case-control study conducted in California 
reported that men between ages 20 and 29 years have a decreased prostate cancer risk 
(OR=0.53, 95% CI: 0.28, 1.00) and BMI ≥ 30 kg/m2 (OR=0.40, 95% CI: 0.20, 0.81) 
compared to BMI <25 kg/m2.35  Giovannucci et al. have also shown similar findings in 
their analysis of the Health Professionals follow-up study. They reported that BMI ≥ 26 
kg/m2 compared to BMI <20 kg/m2 at age 21 was inversely associated with prostate 
cancer risk but this association was not statistically significant (RR=0.87, 95% CI: 0.67, 
1.12). Further BMI ≥ 26 kg/m2 was associated with significant decreased risk in 
advanced prostate cancer (RR=0.53, 95% CI: 0.33, 0.86) compared to BMI <20 kg/m2 
and BMI 24-25.9 kg/m2 was associated with significant decreased risk in metastatic 
prostate cancer compared to BMI <20 kg/m2 (RR=0.46, 95% CI: 0.27, 0.81).28   
Although this study was consistent with some studies described above, the finding 
of this study was contradictory with other studies. Schuurman et al. in the prospective 
Netherlands cohort study that examined about 60,000 men reported that men with BMI ≥ 
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25 kg/m2 at age 20 compared to those with BMI <19 kg/m2 were 1.33 times more likely to 
develop prostate cancer (RR=1.33, 95% CI: 0.81, 2.19).27  A cohort study of the 
participants from the Harvard alumni health study with anthropometric measurements 
measured at age 18 showed a non statistical significant increased risk of developing 
prostate cancer among men with BMI ≥ 25 kg/m2  compared to BMI < 20 kg/m2 
(RR=1.17, 95% CI: 0.40, 1.85).23  The follow-up Norwegian study on 950,000 men 
measured height and weight between 20-74 years also reported a non-statistically 
significant risk of prostate cancer. The study showed that men in the ages 20-29 years 
with BMI ≥ 30 kg/m2 were 1.22 times more likely to develop prostate cancer compared to 
men with BMI < 18.50 kg/m2 (RR=1.22, 95% CI: 0.69, 2.17).13  The discrepant findings 
between our study and these studies could be due to limited control for confounding in 
these past studies. It is important to note that though some of the past studies studying the 
association between early-onset obesity and prostate cancer were prospective cohort 
studies, most of the height and weight data collected for the early ages are usually self-
reported and therefore subject to the same problems as a retrospective study.  
While this study found a statistically significant association between BMI at age 
18 and risk of prostate cancer when BMI was analyzed as continuous variable, the 
association was lost when BMI was categorized.  This could be attributed to the loss of 
information when the variable was categorized.  
The current study observed that there was a 3% decrease in the odds of prostate 
cancer risk for a unit increase in BMI when current BMI was examined as a continuous 
variable but it was not statistically significant (OR=0.97, 95% CI: 0.92, 1.02). There was 
only one other study that evaluated baseline BMI as continuous variable and they found 
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no association between 2 kg/m2 increase in BMI and prostate cancer risk (RR=1.00, 95% 
CI: 0.92, 1.07). This study only adjusted for age, family history of prostate cancer and 
socioeconomic status.27  
Our study showed that there was significant interaction between age and current 
BMI on prostate cancer risk when BMI was evaluated as a categorical variable. There 
was a trend towards decreased risk of prostate cancer with the overweight and obese men 
in the different age groups except the overweight men in 60 years or younger age group. 
This finding was similar to the results observed by Giovannucci et al. However, the study 
by Giovannucci et al. showed a statistically significant decreased prostate cancer risk 
among men less than 60 years old in the two obese categories 27.5-29.9 kg/m2 (RR=0.49, 
95% CI: 0.32, 0.73) and ≥30kg/m2 (RR=0.52, 95% CI: 0.33, 0.83) categories compared 
to men in lower BMI category 23-24.9 kg/m2.8  This difference could be attributed to the 
fact that Giovannucci et al. conducted a prospective cohort study with over 50,000 
participants and also used six categories to define BMI. 
The associated metabolic syndrome observed in obesity may be an explanation 
for the observed association between BMI and risk of prostate cancer. Obesity is 
associated with diabetes later in life and they also occur together in metabolic syndrome. 
Diabetes has been reported to be associated with lower risk of developing prostate cancer 
due to decreased insulin levels and decreased IGF-1 activity.30, 46, 47 This may be a reason 
for the protective effect observed in this study. But this study did not collect information 
on history of diabetes.  
There are several proposed biological and hormonal risk factors for prostate 
cancer that could explain the observed association between increased BMI and risk of 
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prostate cancer. One of these factors is increased insulin and IGF-1 that may be 
associated with obesity. Obesity is associated with endocrinal imbalances leading to 
insulin resistance that causes compensatory hyperinsulinemia and increased IGF-1. 
Studies have shown association between IGF-1 and increased prostate cancer risk.48, 49, 50, 
51, 52, 53      
Another risk factor that may explain the observed association between BMI and 
risk of prostate cancer may also be the decreased levels of testosterone. Testosterone is 
needed for normal prostate cancer epithelium differentiation. But obesity decreases the 
serum testosterone and increases the estrogen levels. The increased estrogen level is also 
due to peripheral conversion of serum testosterone into estradiol.54  Further, the estradiol 
inhibits the pituitary-hypothalamic axis causing decreased testosterone levels.54  Obesity 
also reduces the sex hormone-binding globulin that decreases the serum testosterone 
levels.55  Studies have shown that lower testosterone levels are associated with increased 
prostate cancer risk.56, 57   
The third risk factor that is implicated in prostate cancer risk is leptin; a cytokine 
and polypeptide hormone that is produced by the adipocytes and maintains the body 
weight is implicated in prostate cancer risk. However, it is important to note that studies 
have produced mixed findings with some showing positive association and others 
showing no significant association between leptin and the risk of prostate cancer..58, 59, 60, 
61, 62, 63 However, this study was unable to confirm these proposed associations as these 
biological factors were not measured.            
There are other proposed non-biological causes for the apparent decreased risk of 
prostate cancer with obesity. Two studies have shown that obese men are more likely to 
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get PSA screening.64, 65 However, obese men have low PSA levels making the detection 
of early cancers through PSA screening difficult66, 67, 68 and making them more likely to 
be diagnosed in later advanced stages after symptoms appear. The reason for the low 
PSA levels may include that obese men have high plasma volume causing hemodilution 
and therefore low PSA levels. Also prostate cancer is an androgen-dependent tumor and 
have been shown to be associated with low testosterone levels. The low testosterone 
levels may also cause the low PSA levels as testosterone is needed to produce PSA.69 Our 
study population may include more early stage cancers causing the apparent protective 
effect however stage and grade information was not collected to confirm this hypothesis. 
 Obese men may also less likely to be diagnosed with low grade cancers because 
of the difficulty to conduct digital rectal examinations (DRE) in them though no studies 
support this theroy. DRE, biopsy and PSA screening are the main modalities to diagnose 
prostate cancer. Obese men have larger prostates that have been shown in studies.70, 71 
This makes the routine biopsies very difficult to diagnose the cancer and it can be easily 
missed. Therefore it is recommended to correct the PSA levels for obese men by 
multiplying PSA level by a factor of 1.05 and also taking two additional cores in the 
biopsy to make sure the cancer is not missed.69   
Potential strengths of this study include collecting height and weight information 
both at age 18 and current using standardized validated questionnaires, good response 
rate to mail surveys, and thorough collection of data and control of known and potential 
confounders. Despite the above strengths this study also presents with some limitations. 
Limitations include that height and weight information was self-reported and there is a 
possibility of misclassification of the BMI data. Study by Stevens et al. have shown that 
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reported and measured weight both current and four years prior are highly correlated 
(correlation coefficient 0.979 and 0.935) but decreased for weight 28 years ago 
(correlation coefficient 0.822).72  Participants in the lower quartile of BMI overestimated 
their weight and those in the higher quartile of BMI underestimated their weight.72  It is 
likely that the current study could have overestimated the association since cases may 
have over reported the exposure while controls may have under reported it. Crude 
estimates were calculated using the proportion of obesity in cases and controls from the 
Prostate cancer prevention trial data.73 This gave us results consistent to estimates 
obtained in the current study. There is a potential for recall bias as the study participants 
have been recalling weight and height information at age 18. But if the cases recall 
information differently than the controls that would have caused overestimation of the 
estimates but the current study showed protective effect.  
This study used BMI instead of other measure of central obesity including waist 
to hip ratio. It is believed that in elderly there is a shift in fat from periphery to center that 
can cause a change in waist to hip ratio without changing the BMI. This can cause an 
underestimation of the estimates and show a spurious decreased prostate cancer risk. 
Measuring BMI is easy and studies have shown consistent findings whether they used 
BMI or waist to hip ratio.8 Clinic controls were used and they may be different from the 
general population controls by the fact that they attended the urology clinic. They may 
share similar risk factors as the cases and may underestimate the association between 
obesity and prostate cancer risk. But patients with any urological cancer and prostate-
related problem were excluded and controls were selected from a variety of diagnosis to 
reduce misclassification of controls. Since the cases were selected from this clinic, it is a 
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preferred population to select the controls from the same clinic to be comparable. This 
study was able to obtain a 37% response rate (53% among cases and 29% among 
controls). There may be a difference between the responders and non-responders, 
however, data on non-responders were not available for further analysis. It is possible 
that non-responders were less healthy than the responders underestimating the 
association.  The current study was conducted in a large urology clinic and there is a 
possibility that patients from other locations may be referred to this clinic. This can cause 
an overestimation of the association. But we do not expect differential referral patterns 
between cases and controls as both of these groups were urology patients. 
The present study showed that there was an association between obesity at age 18 
and prostate cancer risk. It is important to continuously monitor and study the lifecycle of 
obesity at early ages in a large prospective study to understand the stage of obesity 
associated with prostate cancer risk. Obesity has other deleterious effects on heath and 
findings of this study should be interpreted with caution. Further studies are needed to 
explore the biological factors influencing the association of increased BMI and risk of 
prostate cancer, especially in the early ages of life. 
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Table 1: Characteristics of the study population  
 Cases (%) Controls (%) Total (%) 
Age (Years)    
≤60 70 (13.2) 375 (59.7) 445 (38.4) 
61-70 183 (34.4) 175 (27.9) 358 (30.9) 
>70 279 (52.4) 78 (12.4) 357 (30.8) 
Race    
White 474 (81.0) 563 (83.0) 1037 (82.1) 
African American 63 (10.8) 63 (9.3) 126 (10.0) 
Hispanic  40 (6.8) 33 (4.9) 73 (5.8) 
Other 8 (1.4) 19 (2.8) 27 (2.1) 
Marital status    
Married 498 (83.7) 557 (82.0) 1055 (82.8) 
Divorced 90 (15.1) 95 (14.0) 185 (14.5) 
Never Married 7 (1.2) 27 (4.0) 34 (2.7) 
Education    
<Grade 12  80 (13.8) 41 (6.2) 121 (9.8) 
Grades 12 or GED 113 (19.5) 147 (22.2) 260 (21.0) 
Some college  126 (21.8) 172 (26.0) 298 (24.0) 
College graduate 260 (44.9) 301 (45.5) 561 (45.2) 
Household income    
< $25,000 69 (14.0) 55 (9.0) 124 (11.2) 
$25,000 to < $50,000 132 (26.8) 107 (17.5) 239 (21.7) 
$50,000 to < $75,000 95 (19.3) 134 (21.9) 229 (20.7) 
$75,000 to < $100,000 74 (15.0) 100 (16.4) 174 (15.8) 
≥ $100,000 123 (25.0) 215 (35.2) 338 (30.6) 
BMI    
≤24.99 178 (30.5) 145 (21.6) 323 (25.7) 
25-29.99 281 (48.2) 302 (44.9) 583 (46.4) 
≥30 124 (21.3) 226 (33.6) 350 (27.9) 
BMI at 18    
≤24.99 438 (85.2) 465 (77.6) 903 (81.1) 
25-29.99 68 (13.2) 119 (19.9) 187 (16.8) 
≥30 8 (1.6) 15 (2.5) 23 (2.1) 
FH of Prostate cancer    
Yes  154 (34.4) 91 (15.9) 245 (24.0) 
No 294 (65.6) 480 (84.1) 774 (76.0) 
Moderate activity (in days 
per week) 
   
0 82 (15.1) 106 (16.6) 188 (15.9) 
1-2 86 (15.8) 124 (19.4) 210 (17.8) 
≥3 377 (69.2) 408 (64.0) 785 (66.4) 
Alcohol (drinks per day)    
0 203 (39.1) 174 (28.8) 377 (33.5) 
1-2 285 (54.9) 391 (64.6) 676 (60.1) 
≥3 31 (6.0) 40 (6.6) 71 (6.3) 
Smoking    
Current smoker 43 (7.2) 87 (12.7)  130 (10.1) 
Former smoker 62 (10.3) 46 (6.7) 108 (8.4) 
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 Cases (%) Controls (%) Total (%) 
Non-smoker 495 (82.5) 553 (80.6) 1048 (81.5) 
Fruits and Vegetables 
(servings per day) 
   
<2 145 (25.3) 208 (31.1) 353 (28.4) 
2-4 264 (46.1) 305 (45.6) 569 (45.8) 
>4 164 (28.6) 156 (23.3) 320 (25.8) 
Milk (servings)    
Never 52 (9.0) 60 (9.2) 112 (9.2) 
At least 1 time per week 328 (57.0) 397 (61.2) 725 (59.2) 
≥1 time per day 195 (33.9) 192 (29.6) 387 (31.6) 
Vitamin intake    
Yes 390 (66.0) 418 (61.8) 808 (63.8) 
No 201 (34.0) 258 (38.2) 459 (36.2) 
Vasectomy    
Yes 155 (27.4) 193 (29.0) 348 (28.3) 
No 411 (72.6) 473 (71.0) 884 (71.8) 
STD    
Yes 50 (8.6) 84 (12.4) 134 (10.7) 
No 530 (91.4) 592 (87.6) 1122 (89.3) 
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Table 3: Interaction between current BMI and age  
 
 BMI 
Age ≤ 24.99 >24.99 and ≤29.99 >29.99 
≤60 1.00 1.01 (0.59, 1.74) 0.73 (0.38, 1.40) 
61-70 1.00 0.73 (0.34, 1.57) 0.44 (0.18, 1.10) 
>70 1.00 0.71 (0.27, 1.87) 0.74 (0.22, 2.56) 
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Figure 1: Interaction between current BMI and age  
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APPENDIX B 
 
 
Data abstraction form 
 
 
Part I: Cover Sheet 
 
 
ID Number:                                                      Reviewer 1:                                                                           
                                                                          Reviewer 2: 
 
 
 
 
Author(s):  
 
 
Title:  
 
 
Journal of Publication and date:  
 
 
Peer reviewed:  
 
Yes  
No  
Unknown  
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ID Number:                                                      Reviewer 1:                                                                           
                                                                          Reviewer 2: 
 
Part II: Criteria for Selection of Articles 
 
Studies will be selected for inclusion if all of the following are answered in the affirmative. 
1. Sources for selected articles: Computerized search from Medline/Web of 
Science/Psycinfo/CINAHL and/or relevant articles referenced in the papers 
identified by computerized search. 
a. Yes 
b. No 
c. Other 
d. Unknown 
2. The year of journal publication was during January 1968 – December 2007. 
a. Yes 
b. No 
c. Unknown 
3. The type of study design was either a prospective or retrospective cohort 
study/case-control study or clinical trial. 
a. Yes 
b. No 
c. Unknown 
4. The study participants had localized (stages I and II) or advanced (stages III and 
IV) prostate cancer. 
a. Yes 
b. No 
c. Unknown 
5. Race (Caucasian/African American) was the main exposure or at least one of the 
exposure variables. 
a. Yes 
b. No 
c. Unknown 
6. Survival (All-cause or cause-specific) was the outcome or at least one of the 
outcomes. 
a. Yes 
b. No 
c. Unknown 
7. Article 
a. Accepted 
b. Rejected 
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ID Number:                                                      Reviewer 1:  
                                                                          Reviewer 2: 
 
 
Part III: Data Extraction Form 
 
1. Study location:  
 
2. Study name: 
 
3. Study type:  
 
4. Data source:  
 
5. Cohort characteristics: 
 
a. Age:  
 
b. Race: 
i. White  
ii. Black  
iii. Other  
 
c. Stage of cancer: (TNM/AJCC/Jewett) 
i. Localized  
ii. Regional  
iii. Advanced  
 
d. Grade of cancer or Gleason score: 
i. Grade I (well differentiated)  
ii. Grade II (moderately differentiated)  
iii. Grade III (poorly differentiated)  
iv. Grade IV (undifferentiated and unknown)  
 
6. Number of subjects (sample size):  
 
7. Year of prostate cancer diagnosis:  
 
8. Length of follow-up (years):  
 
9. Races assessed: 
a. White  
b. Black  
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c. Hispanic  
d. American Indian  
e. Asian  
f. Other  
 
10. Survival status assessed: 
a. All-cause survival   
b. Prostate cancer-specific survival  
 
11. Other covariates assessed:  
 
 
12. Covariates controlled for:  
a. Age  
b. Race 
c. Stage 
d. Grade 
e. SES (education and income level) 
f. Comorbidity 
g. Year of diagnosis 
h. Treatment 
i. Geographic area 
j. Marital status 
k. Preoperative PSA level 
l. Gleason score 
 
13. Result: 
a. Kaplan-Meier survival curves: -------------------------------------------------- 
 
b. 5-yr relative survival : -------------------------------------------------- 
 
c. Hazard ratio: ---------------------------------------------------- 
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APPENDIX C 
 
 
Case-control study questionnaire 
 
Prostate Health Study 
 
 
Instruction: Please complete the following questions to the best of your knowledge. 
Please check the box or fill the blanks corresponding to the appropriate response. 
 
1. In the table below, please indicate which of your biological (blood-related) family 
members have been diagnosed with cancer, what kind of cancer they had, and how old 
they were when they were diagnosed. Also please tell us about any cancer you have 
had. 
 
Is this relative on your 
mother or your father’s side 
of the family? 
 
 
Relative (or self) 
Mother’s side Father’s side 
 
 
Kind of cancer 
 
 
Age diagnosed 
 
 
Died from 
cancer? 
Example: Grandmother [X] [  ] Colon 54 Years No 
Example: Uncle [  ] [X] Unknown Unknown Yes 
 [  ] [  ]    
 [  ] [  ]    
 [  ] [  ]    
 [  ] [  ]    
 [  ] [  ]    
 [  ] [  ]    
 [  ] [  ]    
 [  ] [  ]    
 [  ] [  ]    
 
2. About how much do you weigh without shoes?  
_ _ _ _ Weight  
(pounds)  
 Don’t know / Not sure  
 
3. About how tall are you without shoes? 
 _ _ / _ _ Height  
(f t / inches)  
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 Don’t know / Not sure 
 
4. What was your weight at age 18? 
_ _ _ _ Weight  
(pounds)  
 Don’t know / Not sure  
 
5. Within the last 20 years (exclude illness): 
a. What was your: Minimum weight _ _ _ _ lbs         At what age? _ _ _ age 
                                  
                                Maximum weight _ _ _ _ lbs        At what age? _ _ _ age 
 
b. Within the last 20 years, how many times did you lose each of the following 
amounts of weight on purpose (exclude illness): 
 
5-9 lbs       O 0 times   O 1-2 times   O 3-4 times   O 5-6 times   O 7+ times 
10-19 lbs   O 0 times   O 1-2 times   O 3-4 times   O 5-6 times   O 7+ times 
20-49 lbs   O 0 times   O 1-2 times   O 3-4 times   O 5-6 times   O 7+ times 
50+ lbs      O 0 times   O 1-2 times   O 3-4 times   O 5-6 times   O 7+ times 
 
6. On an average, how many days per week do you do moderate activities (such as 
brisk walking, bicycling, vacuuming, gardening or anything else that causes 
some increase in breathing or heart rate) for at least 30 minutes at a time?  
_ _ Days per week 
 Do not do any moderate physical activity for at least 30 minutes at a time 
 Don’t know / Not sure  
 
7. On an average, how often did you drink any type of alcoholic beverage? How 
many days per week, per month or per year did you drink? (Select only one 
response) 
_ _ days per week  
_ _ days per month 
_ _ days per year   
 Don’t drink 
 Don’t know/not sure 
 
8. On those days that you drank alcoholic beverages, on the average, how many 
drinks did you have?  
_ _ _ _ number of drinks 
 Don’t know/not sure 
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If you are a current or former smoker, answer the following questions and if you are a 
non-smoker, skip to question number 12. 
 
9. If you are a current smoker, how long have you been smoking?  
_ _ number of years 
 Don’t know / Not sure  
 
10. Do you now smoke cigarettes every day, some days, or not at all?  
 Every day  
 Some days  
 Not at all   
 Don’t know / Not sure  
 
11. On average, about how many cigarettes a day do you smoke? (1 pack = 20 
cigarettes)  
_ _ number of cigarettes 
 Varied 
 Never smoked cigarettes regularly 
 Don’t know/not sure 
 
12. On an average, when you go outside on a warm sunny day for more than one 
hour, how often do you stay in the shade? (this has to be considering your past 
practices) 
 Always 
 Most of the time 
 Sometimes 
 Rarely 
 Never 
 Don’t go out in the sun 
 Don’t know/not sure 
 
13. On an average, when you go outside on a warm sunny day for more than one 
hour, how often do you wear a baseball cap or sun visor? (this has to be 
considering your past practices) 
 Always 
 Most of the time 
 Sometimes 
 Rarely 
 Never 
 Don’t go out in the sun 
 Don’t know/not sure 
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14. On an average, when you go outside on a warm sunny day for more than one 
hour, how often do you wear a long sleeved shirt, long pants or other clothing 
that reaches the ankles? (this has to be considering your past practices) 
 Always 
 Most of the time 
 Sometimes 
 Rarely 
 Never 
 Don’t go out in the sun 
 Don’t know/not sure 
 
15. On an average, when you go outside on a warm sunny day for more than one 
hour, how often do you use sunscreen? (this has to be considering your past 
practices) 
 Always 
 Most of the time 
 Sometimes 
 Rarely 
 Never 
 Don’t go out in the sun 
 Don’t know/not sure 
 
16. On an average, how often do you drink fruit juices such as orange, grapefruit or 
tomato? (this has to be considering your past practices, select only one 
response) 
_ _ per day  
_ _ per week  
_ _ per month  
_ _ per year  
 Never 
 Don’t know/not sure 
 
17. On an average, not counting juice, how often do you eat fruit? (this has to be 
considering your past practices, select only one response) 
_ _ per day  
_ _ per week  
_ _ per month  
_ _ per year  
 Never 
 Don’t know/not sure 
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18. On an average, how often do you eat green salad? (this has to be considering 
your past practices, select only one response) 
_ _ per day  
_ _ per week  
_ _ per month  
_ _ per year  
 Never 
 Don’t know/not sure 
 
19. On an average, how often do you eat carrots? (this has to be considering your 
past practices, select only one response) 
_ _ per day  
_ _ per week  
_ _ per month  
_ _ per year  
 Never 
 Don’t know/not sure 
 
20. On an average, not counting carrots, potatoes or salad, how many servings of 
vegetables do you usually eat? (Example: A serving of vegetables at both lunch 
and dinner would be two servings.) (this has to be considering your past 
practices, select only one response) 
_ _ per day  
_ _ per week  
_ _ per month  
_ _ per year  
 Never 
 Don’t know/not sure 
 
21. On an average, how often did you have milk, either to drink or on cereal? 
(Include skim, no-fat, low-fat, whole milk, buttermilk, lactose-free milk, 
chocolate or other flavored milks) (this has to be considering your past 
practices, select only one response) 
 Never 
 1-2 times per week 
 3-4 times per week 
 5-6 times per week 
 1 time per day 
 2 times per day 
 3 times per day 
 4 times per day 
 5 or more times per day 
 Don’t know/not sure 
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22. On an average, do you take any vitamin or mineral supplements of any kind? 
(this has to be considering your past practices)  
 Yes 
 No 
 Don’t know/not sure 
 
23. On an average, how long have you used multi-vitamins.? (this has to be 
considering your past practices, select only one response) 
_ _ months  
_ _ years  
 Don’t know/not sure 
 
24. Did you ever have a vasectomy?  
 Yes  
 No  
 Don’t know / Not sure  
 
25. Have you ever had a sexually transmitted disease like syphilis, gonorrhea, 
Chlamydia, genital herpes or warts?  
 Yes  
 No  
 Don’t know / Not sure  
 
26. How old are you? _ _ _Years 
 
27. Which one or more of the following would you say is your race?  
(Check all that apply) 
 Non-Hispanic White 
 Hispanic White 
 Non-Hispanic Black or African American 
 Hispanic Black or African American 
 Asian 
 Native Hawaiian or Other Pacific Islander 
 American Indian or Alaska Native 
 Other [specify]______________ 
 Don’t know/not sure 
 
28. What is your marital status?  
 Married 
 Divorced 
 Widowed 
 Separated 
   
 112 
 Never married 
 A member of an unmarried couple 
 
29. What is the highest grade or year of school you completed?  
 Never attended school or only attended kindergarten  
 Grades 1 through 8 (Elementary) 
 Grades 9 through 11 (Some high school) 
 Grade 12 or GED (High school graduate) 
 College 1 year to 3 years (Some college or technical school)  
 College 4 years or more (College graduate) 
 Don’t know/not sure 
 
30. What is your current occupation?  
 Employed for wages 
 Self-employed 
 Out of work for more than 1 year 
 Out of work for less than 1 year 
 A Homemaker 
 A Student 
 Retired  
 Unable to work  
 
31. Is your annual household income from all sources?  
 Less than $10,000  
 10,000 to less than $15,000 
 $15,000 to less than $20,000 
 $20,000 to less than $25,000 
 $25,000 to less than $35,000 
 $35,000 to less than $50,000 
 $50,000 to less than $75,000 
 $75,000 to less than $100,000 
 $100,000 or more  
 Don’t know / Not sure 
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